Drug Type Small molecule drug |
Synonyms A 295, A295 |
Target |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists), A2bR antagonists(Adenosine A2b receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization KLUS Pharma, Inc.Startup |
Active Organization KLUS Pharma, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | KLUS Pharma, Inc.Startup | 15 Aug 2023 |